{"id":724898,"date":"2023-01-23T07:05:24","date_gmt":"2023-01-23T12:05:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/"},"modified":"2023-01-23T07:05:24","modified_gmt":"2023-01-23T12:05:24","slug":"lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/","title":{"rendered":"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium"},"content":{"rendered":"
\n

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) — LAVA<\/u>Therapeutics<\/u>N.V.<\/u><\/a>(Nasdaq:<\/u>LVTX<\/u><\/a>), an immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1\/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023.<\/p>\n

The details of the poster presentation are as follows:<\/p>\n

\n Abstract #:\u00a0<\/strong>153
Abstract Title:\u00a0<\/strong>Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T cell engager (Gammabody\u2122), in metastatic castration-resistant prostate cancer (mCRPC) patients<\/em>
Session Title:\u00a0<\/strong>Poster Session A: Prostate Cancer
Poster Board #:<\/strong> E13
Session Date: <\/strong>Thursday, February 16, 2023
Session Times:<\/strong> 11:30 AM-1:00 PM PT and 5:45 PM-6:45 PM PT
Presenter<\/strong>: Niven Mehra, Radboud University Medical Center, Department of Medical Oncology MD, PhD<\/p>\n

\n About LAVA Therapeutics<\/strong>
\n
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody\u2122 platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering V\u03b39V\u03b42 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company\u2019s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1\/2a clinical study (NCT04887259). A Phase 1\/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.<\/p>\n

\n LAVA\u2019s<\/strong>
\n Cautionary<\/strong>
\n Note<\/strong>
\n on<\/strong>
\n Forward-Looking<\/strong>
\n Statements<\/strong>
\n
\n This press release contains forward-looking statements, including in respect to the company\u2019s anticipated<\/em>
\n growth and clinical developments plans, and the timing and results of clinical trials. Words such as \u201canticipate,\u201d<\/em>
\n \u201cbelieve,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cpotential\u201d and similar<\/em>
\n expressions<\/em>
\n (as<\/em>
\n well<\/em>
\n as<\/em>
\n other<\/em>
\n words<\/em>
\n or<\/em>
\n expressions<\/em>
\n referencing<\/em>
\n future<\/em>
\n events,<\/em>
\n conditions<\/em>
\n or<\/em>
\n circumstances)<\/em>
\n are intended to identify forward-looking statements. These forward-looking statements are based on<\/em>
\n LAVA\u2019s expectations and assumptions as of the date of this press release and are subject to various risks<\/em>
\n and<\/em>
\n uncertainties<\/em>
\n that<\/em>
\n may<\/em>
\n cause<\/em>
\n actual<\/em>
\n results<\/em>
\n to<\/em>
\n differ<\/em>
\n materially<\/em>
\n from<\/em>
\n these<\/em>
\n forward-looking<\/em>
\n statements. Forward-looking statements contained in this press release include, but are not limited to,<\/em>
\n statements about the preclinical and clinical data, clinical development and scope of clinical trials, and the potential<\/em>
\n use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may<\/em>
\n cause differences between current expectations and actual results including, among other things, the<\/em>
\n timing<\/em>
\n and<\/em>
\n results<\/em>
\n of<\/em>
\n our<\/em>
\n research<\/em>
\n and<\/em>
\n development<\/em>
\n programs<\/em>
\n and<\/em>
\n preclinical<\/em>
\n and<\/em>
\n clinical<\/em>
\n trials,<\/em>
\n our<\/em>
\n ability<\/em>
\n to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our<\/em>
\n initial programs to develop <\/em>
\n additional product candidates using our Gammabody\u2122<\/em>
\n \u00a0platform, and the<\/em>
\n failure<\/em>
\n of<\/em>
\n LAVA\u2019s<\/em>
\n collaborators<\/em>
\n to<\/em>
\n support<\/em>
\n or<\/em>
\n advance<\/em>
\n collaborations<\/em>
\n or<\/em>
\n our<\/em>
\n product<\/em>
\n candidates. The COVID-19 pandemic may disrupt our business and that of the third parties on which we depend,<\/em>
\n including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and<\/em>
\n supply chain, or impairing employee productivity. In addition, there may be adverse effects on our business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including deteriorating market conditions due to investor concerns regarding inflation and hostilities between Russia and Ukraine. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information<\/em>
\n becomes available.<\/em>\n <\/p>\n

\n
\n CONTACTS<\/u>
\n <\/strong>
\n
Investor Relations
ir@lavatherapeutics.com<\/a>\u00a0<\/p>\n

Argot Partners (IR\/Media)
212-600-1902
lava@argotpartners.com<\/a>\u00a0<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1\/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023. The details of the poster presentation are as follows: Abstract #:\u00a0153Abstract Title:\u00a0Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T cell engager (Gammabody\u2122), in metastatic castration-resistant prostate cancer (mCRPC) patientsSession Title:\u00a0Poster Session A: Prostate CancerPoster Board #: E13Session Date: Thursday, February 16, … <\/p>\n

Continue reading “LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-724898","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1\/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023. The details of the poster presentation are as follows: Abstract #:\u00a0153Abstract Title:\u00a0Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T cell engager (Gammabody\u2122), in metastatic castration-resistant prostate cancer (mCRPC) patientsSession Title:\u00a0Poster Session A: Prostate CancerPoster Board #: E13Session Date: Thursday, February 16, … Continue reading "LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T12:05:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium\",\"datePublished\":\"2023-01-23T12:05:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/\"},\"wordCount\":633,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/\",\"name\":\"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=\",\"datePublished\":\"2023-01-23T12:05:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/","og_locale":"en_US","og_type":"article","og_title":"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium - Market Newsdesk","og_description":"UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) — LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1\/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco from February 16-18, 2023. The details of the poster presentation are as follows: Abstract #:\u00a0153Abstract Title:\u00a0Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T cell engager (Gammabody\u2122), in metastatic castration-resistant prostate cancer (mCRPC) patientsSession Title:\u00a0Poster Session A: Prostate CancerPoster Board #: E13Session Date: Thursday, February 16, … Continue reading \"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-23T12:05:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium","datePublished":"2023-01-23T12:05:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/"},"wordCount":633,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/","name":"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=","datePublished":"2023-01-23T12:05:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczMzU5MCM1MzY2Mjk3IzIyMDY3OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lava-therapeutics-to-present-lava-1207-clinical-data-at-the-2023-asco-gu-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=724898"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724898\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=724898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=724898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=724898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}